Compounding Pharmacy Market Size to Garner USD 28.19 Billion by 2032

The global compounding pharmacy market size was estimated to be around US$ 14.92 billion in 2022. It is projected to reach US$ 28.19  billion by 2032, indicating a CAGR of 6.57% from 2023 to 2032.

Key Takeaways:

• North America is expected to dominate the market during the forecast period.
• By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
• By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
• By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.

The market research report on the Compounding pharmacy market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Compounding pharmacy products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.

Get a Sample: https://www.precedenceresearch.com/sample/3185

Compounding Pharmacy Market Report Scope

Read More: Grow Lights Market Size to Garner USD 24.44 Billion by 2032

The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.

Focusing on the global Compounding pharmacy market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Compounding pharmacy market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.

Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Compounding pharmacy products across different countries and applications.

Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.

The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.

This in-depth research report offers valuable insights into the Compounding pharmacy market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.

The competitive landscape section of the report provides detailed information on Compounding pharmacy market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Compounding pharmacy market.

Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report

Reasons to Purchase this Report:

• Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
• In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
• Market size in USD million and volume in million units provided for each segment and sub-segment.
• Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
• Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Key Players

• Fresenius Kabi
• Fagron NV
• B. Braun Medical Inc.
• Rx3 Compounding Pharmacy
• Clinigen Group PLC
• Dougherty’s Pharmacy, Inc.
• Lorraine’s Pharmacy
• Wedgewood Pharmacy
• Institutional Pharmacy Solutions
• Mcguff compounding pharmacy services

Compounding Pharmacy Market Segmentations

By Therapeutic Area

• Pain Management
• Hormone Replacement
• Dermal Disorders
• Nutritional Supplements
• Others

By Route of Administration

• Oral
• Topical
• Parenteral
• Others

By Application

• Pediatric
• Geriatric
• Adult
• Veterinary

By Compounding Type

• Pharmaceutical Dosage Alteration (PDA)
• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Others

By Sterility

• Sterile
• Non-sterile

By Distribution Channel

• Compounding Pharmacy
• Hospital Pharmacy
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Compounding Pharmacy Market 

5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area

8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032

8.1.1. Pain Management

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hormone Replacement

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Dermal Disorders

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Nutritional Supplements

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Compounding Pharmacy Market, By Route of Administration

9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Compounding Pharmacy Market, By Application

10.1. Compounding Pharmacy Market, by Application, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Geriatric

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Adult

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Veterinary

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Compounding Pharmacy Market, By Compounding Type

11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032

11.1.1. Pharmaceutical Dosage Alteration (PDA)

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Pharmaceutical Ingredient Alteration (PIA)

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Compounding Pharmacy Market, By Sterility

12.1. Compounding Pharmacy Market, by Sterility, 2023-2032

12.1.1. Sterile

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Non-sterile

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel

13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032

13.1.1. Compounding Pharmacy

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Hospital Pharmacy

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Others

13.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 15. Company Profiles

15.1. Fresenius Kabi

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Fagron NV

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. B. Braun Medical Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Rx3 Compounding Pharmacy

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Clinigen Group PLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Dougherty’s Pharmacy, Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Lorraine’s Pharmacy

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Wedgewood Pharmacy

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Institutional Pharmacy Solutions

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Mcguff compounding pharmacy services

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com